



April 28, 2014

## **Acura Pharmaceuticals to Host First Quarter 2014 Financial Results Conference Call on May 6, 2014**

PALATINE, IL -- (Marketwired) -- 04/28/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating [abuse deterrent drugs](#), today announced that the Company plans to report financial results for the first quarter 2014 following the close of financial markets on Monday, May 5, 2014. The Company will host a conference call to discuss the results on Tuesday, May 6, 2014 at 8:30 a.m. ET.

To participate in the live conference call, please dial **1-888-428-9473** (U.S. and Canada) five to ten minutes prior to the start of the call. The participant passcode is **9678956**. A replay of the call will be available beginning May 6, 2014 at 11:30 a.m. ET and ending on May 26, 2014 on the company's website, and by dialing **1-888-203-1112** (U.S. and Canada). The replay participant code is **9678956**.

### ***About Acura Pharmaceuticals***

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary AVERSION® and IMPEDE® Technologies. AVERSION® contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages. IMPEDE® is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

In June 2011, the U.S. Food and Drug Administration approved OXECTA® (oxycodone HCl tablets) which incorporates the AVERSION® technology. The Company has a development pipeline of additional AVERSION® technology products containing other opioids.

The trademark OXECTA® is owned by Pfizer Inc.

Contact:

***for Acura Investor Relations***

[Email Contact](#)

847-705-7709

***for Acura Media Relations***

[Email Contact](#)

847-705-7709

Source: Acura Pharmaceuticals, Inc.

News Provided by Acquire Media